Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients - results from real-life prospective study.
Horňák T, Semerád L, Žáčková D, Weinbergerová B, Šustková Z, Procházková J, Bělohlávková P, Stejskal L, Rohoň P, Faber E, Žák P, Mayer J, Ráčil Z. Horňák T, et al. Among authors: rohon p. Leuk Lymphoma. 2020 Feb;61(2):494-496. doi: 10.1080/10428194.2019.1672054. Epub 2019 Oct 3. Leuk Lymphoma. 2020. PMID: 31580157 No abstract available.
A significant proportion of patients with chronic myeloid leukemia and suboptimal response according to European Leukemia Net criteria have excellent prognosis without treatment change.
Rohon P, Faber E, Divoka M, Rozmanova S, Friedecky D, Jarosova M, Indrak K. Rohon P, et al. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013 Jun;157(2):181-8. doi: 10.5507/bp.2011.059. Epub 2011 Nov 30. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013. PMID: 22660209 Free article.
Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients.
Polivkova V, Rohon P, Klamova H, Cerna O, Divoka M, Curik N, Zach J, Novak M, Marinov I, Soverini S, Faber E, Machova Polakova K. Polivkova V, et al. Among authors: rohon p. PLoS One. 2016 May 23;11(5):e0155959. doi: 10.1371/journal.pone.0155959. eCollection 2016. PLoS One. 2016. PMID: 27214026 Free PMC article.
Spontaneous splenic rupture in a patient with acute promyelocytic leukaemia during induction chemotherapy.
Kuba A, Szotkowski T, Rohon P, Faber E, Turcsanyi P, Hubacek J, Holzerova M, Prasil V, Jarosova M, Indrak K. Kuba A, et al. Among authors: rohon p. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Jun;159(2):294-8. doi: 10.5507/bp.2013.086. Epub 2013 Nov 26. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015. PMID: 24322341 Free article.
Flow cytometric monitoring of the in vitro inhibition of the phosphorylation of CRKL and of SRC family kinases in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors.
Krupkova L, Mojzikova R, Novotny J, Gazdova J, Divoka M, Skoumalova I, Rohon P, Jarosova M, Indrak K, Faber E, Divoky V. Krupkova L, et al. Among authors: rohon p. Int J Lab Hematol. 2015 Feb;37(1):e11-5. doi: 10.1111/ijlh.12258. Epub 2014 May 21. Int J Lab Hematol. 2015. PMID: 24845482 No abstract available.
33 results